
    
      Patients were treated until disease progression, unacceptable toxicity, Investigator's
      decision to discontinue, or withdrawal of consent. After treatment discontinuation, all
      patients were evaluated every 90 days after last dose of gemcitabine/carboplatin with or
      without iniparib, for up to 3 years or death or end of study, which ever occurred first.
    
  